Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inhaled Medications01:23

Inhaled Medications

197
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
197
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

136
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
136
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

122
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
122
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

244
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
244

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Anthocyanin Encapsulation as a Potential Approach for Improving the Quality of Aronia Powder.

Molecules (Basel, Switzerland)·2026
Same author

Correction: Catenacci et al. Effect of Lipid Nanoparticle Physico-Chemical Properties and Composition on Their Interaction with the Immune System. <i>Pharmaceutics</i> 2024, <i>16</i>, 1521.

Pharmaceutics·2026
Same author

Engineering Thermoresponsive In Situ Gels Incorporating Nutraceutical-Laden Nanostructured Lipid Carriers for Controlled Periodontal Drug Release.

Gels (Basel, Switzerland)·2026
Same author

Design and In Vitro Evaluation of Cyclodextrin-Functionalized Albumin Nanoparticles for Intranasal Carbamazepine Brain Delivery.

Pharmaceutics·2026
Same author

Three-Dimensionally Printed Paediatric Medicines: Formulation, Process, and Regulatory Considerations.

Pharmaceutics·2026
Same author

Impact of Different Drying Processes on the Physico-Chemical Properties of Liquitablet Formulations Containing Lornoxicam.

Pharmaceutics·2025

Related Experiment Video

Updated: May 10, 2025

Author Spotlight: Developing a Disposable Dosator for Preclinical Testing of Dry Powder Inhalers in Small Animal Models
04:59

Author Spotlight: Developing a Disposable Dosator for Preclinical Testing of Dry Powder Inhalers in Small Animal Models

Published on: August 18, 2023

769

Nanoparticle-Based Dry Powder Inhaler Containing Ciprofloxacin for Enhanced Targeted Antibacterial Therapy.

Petra Party1, Márk László Klement1, Bianca Maria Gaudio2

  • 1Institute of Pharmaceutical Technology and Regulatory Affairs, University of Szeged, 6720 Szeged, Hungary.

Pharmaceutics
|April 26, 2025
PubMed
Summary

This study developed a nano-in-micro dry powder inhaler (DPI) for ciprofloxacin (CIP) to treat lung infections. The novel formulation enhances drug delivery to the lungs, improving treatment effectiveness and reducing side effects.

Keywords:
aerodynamic characterizationciprofloxacindry powder inhalernanosuspensionspray dryingwet milling

More Related Videos

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

40.5K
Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals
04:22

Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals

Published on: March 30, 2017

7.6K

Related Experiment Videos

Last Updated: May 10, 2025

Author Spotlight: Developing a Disposable Dosator for Preclinical Testing of Dry Powder Inhalers in Small Animal Models
04:59

Author Spotlight: Developing a Disposable Dosator for Preclinical Testing of Dry Powder Inhalers in Small Animal Models

Published on: August 18, 2023

769
Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

40.5K
Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals
04:22

Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals

Published on: March 30, 2017

7.6K

Area of Science:

  • Pharmaceutical Technology
  • Drug Delivery Systems
  • Nanotechnology

Background:

  • Ciprofloxacin (CIP) is a fluoroquinolone antibiotic effective for lung infections.
  • Pulmonary drug delivery requires lower doses than oral administration.
  • Nanoparticle formulations can enhance antibiotic efficacy and reduce side effects.

Purpose of the Study:

  • To develop a "nano-in-micro" dry powder inhaler (DPI) formulation containing ciprofloxacin.
  • To optimize nanoparticle-based pulmonary drug delivery for respiratory infections.

Main Methods:

  • A two-step method involving wet milling to create a nanosuspension, followed by spray drying with additives (leucine, mannitol).
  • Characterization using laser diffraction, nanoparticle tracking analysis, SEM, XRD, and DSC.
  • In vitro solubility, dissolution, and aerodynamic performance testing.

Main Results:

  • Successful preparation of a ciprofloxacin nanosuspension (D50: 140.0 ± 12.8 nm).
  • Developed DPIs exhibited suitable particle size and spherical shape for inhalation.
  • Enhanced drug release due to increased surface area and amorphization.
  • Formulations showed good lung deposition (fine particle fraction ~40%) and aerodynamic diameter (3-4 µm).

Conclusions:

  • Successfully formulated a nanosized ciprofloxacin powder for pulmonary delivery.
  • The nano-in-micro DPI offers a promising approach for treating respiratory infections.
  • This formulation has the potential to improve patient outcomes for lung infections.